{"gene":"PCSK9","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":2003,"finding":"PCSK9 (NARC-1) is a proteinase K-like subtilase that undergoes autocatalytic intramolecular processing of its prosegment at the (Y,I)VV(V,L)(L,M) motif; in vitro peptide processing studies and Ala substitutions of P1–P5 sites established that hydrophobic/aliphatic residues are critical at P1, P3, and P5 for substrate recognition.","method":"Biosynthetic analysis, microsequencing of WT and mutant enzyme, in vitro peptide processing assays, Ala-scanning mutagenesis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution of autocatalytic processing combined with active-site mutagenesis in a dedicated mechanistic study","pmids":["12552133"],"is_preprint":false},{"year":2003,"finding":"Gain-of-function mutations in PCSK9 (S127R and D374Y) cause autosomal dominant hypercholesterolemia, establishing PCSK9 as a genetic determinant of LDL cholesterol metabolism.","method":"Human genetic linkage mapping and mutation identification in ADH kindreds","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — human genetics firmly linked PCSK9 mutations to hypercholesterolemia, replicated broadly","pmids":["12730697"],"is_preprint":false},{"year":2003,"finding":"PCSK9 autocatalytic zymogen processing is Ca2+-independent; Val at P4 and Pro at P3′ are critical for processing at the SSVFAQ↓SIP site. Gain-of-function mutants S127R and D374Y reduce zymogen processing by ~50–60% and ≥98%, respectively, whereas F216L, R218S, and double D374Y+N157K mutants show normal processing.","method":"Biosynthetic analysis of WT and natural mutant NARC-1, site-directed mutagenesis, Ca2+-depletion experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro biochemical reconstitution with mutagenesis across multiple natural variants in a single study","pmids":["15358785"],"is_preprint":false},{"year":2003,"finding":"Overexpression of NARC-1/PCSK9 in stable HepG2 cells reduces LDL receptor (LDLR) levels, an effect abrogated by ammonium chloride, indicating PCSK9 increases LDLR turnover via a lysosomal/endosomal pathway.","method":"Stable HepG2 cell overexpression, Western blot for LDLR, ammonium chloride inhibition of lysosomal degradation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-based loss/gain-of-function with pharmacological pathway dissection; replicated across multiple subsequent studies","pmids":["15358785"],"is_preprint":false},{"year":2003,"finding":"Adenoviral expression of human NARC-1 in mice produces up to ~9-fold increase in circulating LDL cholesterol; in LDLR−/− mice a smaller ~2-fold delayed increase occurs, demonstrating both LDLR-dependent and LDLR-independent effects on LDL.","method":"Adenoviral hepatic overexpression in WT and LDLR−/− mice, plasma LDL measurement","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic model with LDLR knockout epistasis cleanly separating LDLR-dependent from LDLR-independent effects","pmids":["15358785"],"is_preprint":false},{"year":2003,"finding":"NARC-1 autocatalytic processing occurs in the ER, and the mature convertase is secreted from liver and hepatoma cells; PCSK9 shows partial colocalization with clathrin-coated vesicles and LDLR by double immunofluorescence.","method":"Subcellular fractionation, Western blotting, confocal immunofluorescence double-labeling with LDLR and clathrin antibodies","journal":"Biochemistry and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by two orthogonal methods (fractionation + immunofluorescence), single lab","pmids":["16462892"],"is_preprint":false},{"year":2003,"finding":"Rat Narc1 undergoes autocatalytic intramolecular processing at LVFAQ↓, generating an active protease with a broad alkaline pH optimum and no apparent calcium requirement; both primary and secondary structural determinants influence substrate recognition; the enzyme is classified in the proteinase K subfamily.","method":"Functional characterization: recombinant expression, prosegment cleavage assay, pH and calcium-dependence assays, substrate profiling","journal":"Archives of biochemistry and biophysics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical reconstitution with substrate and condition-dependence assays, single lab","pmids":["14622975"],"is_preprint":false},{"year":2006,"finding":"Specific morpholino knockdown of zebrafish NARC-1/PCSK9 mRNA causes disorganization of cerebellar neurons and loss of hindbrain-midbrain boundaries leading to embryonic death, establishing a role for PCSK9 in CNS development distinct from its hepatic cholesterol function.","method":"Whole-mount in situ hybridization, morpholino-mediated knockdown in zebrafish, phenotypic analysis","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function in vivo model with specific neuroanatomical readout; single lab, zebrafish model","pmids":["16893422"],"is_preprint":false},{"year":2006,"finding":"NARC-1/PCSK9 overexpression in cerebellar granule neurons (CGNs) promotes caspase-dependent and caspase-independent apoptosis; mutation of the active-site serine or deletion of the catalytic domain reduces the BAF-sensitive (caspase-dependent) component of cell death, linking the protease activity to pro-apoptotic signaling.","method":"Transfection of EGFP-fusion constructs (WT, active-site mutant, deletion mutants) in primary CGNs; laser scanning cytometry-based cell death scoring; BAF (poly-caspase inhibitor) treatment","journal":"Cytometry Part A","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — active-site mutagenesis with functional cell death readout; single lab, single method platform","pmids":["17051583"],"is_preprint":false},{"year":2008,"finding":"The enzymatic (protease) activity of PCSK9 is not required for LDLR degradation; instead, PCSK9 acts as a chaperone that binds LDLR and targets it for lysosomal degradation. This was demonstrated by site-directed mutagenesis of the catalytic site and crystal structure determination.","method":"Site-directed mutagenesis of catalytic site; crystal structure determination; LDLR degradation assays","journal":"Atherosclerosis","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with catalytic-site mutagenesis, independently confirmed by multiple labs as reviewed","pmids":["18649882"],"is_preprint":false},{"year":2014,"finding":"The catalytic domain of PCSK9 binds to the EGF-A domain of LDLR at the cell surface. Following clathrin-mediated endocytosis, an additional electrostatic interaction at acidic pH between the C-terminal domain of PCSK9 and the ligand-binding domain of LDLR keeps the complex intact in the sorting endosome, preventing LDLR from adopting a closed conformation required for recycling. LDLR ectodomain is subsequently cleaved by a cysteine cathepsin in the sorting endosome, directing it to lysosomal degradation.","method":"Literature synthesis of structural, biochemical, and cell biology studies; mechanistic model supported by referenced crystal structure and endosomal pH-dependence experiments","journal":"Atherosclerosis","confidence":"High","confidence_rationale":"Tier 1 / Strong — mechanistic model supported by crystal structures and multiple independent labs' biochemical data as summarized in review","pmids":["25222343"],"is_preprint":false},{"year":2015,"finding":"LOX-1 and PCSK9 positively regulate each other's expression in vascular endothelial and smooth muscle cells; siRNA knockdown of each reduces the other's expression, and LOX-1 KO mice show reduced PCSK9 and vice versa. Mitochondrial ROS (mtROS) acts as an upstream initiator of this crosstalk, and PCSK9 regulates VCAM-1 expression via NF-κB signaling.","method":"siRNA knockdown, cDNA overexpression, LOX-1 and PCSK9 knockout mice, mtROS inhibition/induction experiments","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal knockdown/overexpression with in vivo KO validation, single lab, two orthogonal approaches","pmids":["26092101"],"is_preprint":false},{"year":2020,"finding":"PCSK9 physically associates with MHC class I proteins on tumor cell surfaces, promotes their relocation and lysosomal degradation, thereby reducing MHC-I cell surface expression; PCSK9 genetic deletion or antibody neutralization increases tumor cell surface MHC-I and enhances intratumoral cytotoxic T cell infiltration, potentiating anti-PD1 immune checkpoint therapy.","method":"Co-immunoprecipitation (physical association), PCSK9 gene deletion in mouse cancer cells, PCSK9 neutralizing antibodies, flow cytometry for MHC-I surface levels, T-cell depletion experiments, syngeneic mouse tumor models","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP plus genetic KO plus antibody neutralization with in vivo tumor readout and T-cell epistasis; multiple orthogonal methods in one study","pmids":["33177715"],"is_preprint":false},{"year":2020,"finding":"NLRP3 inflammasome and its downstream signals (ASC, Caspase-1, IL-1β, IL-18) regulate PCSK9 secretion from macrophages and multiple tissues; IL-1β is identified as more important than IL-18 in inducing PCSK9 secretion; MAPKs are involved. High-fat diet-induced PCSK9 secretion is attenuated in IL-1β-deficient mice.","method":"Gene deletion mice (NLRP3 KO, IL-1β KO, IL-18 KO, caspase-1 KO), mouse peritoneal macrophages in vitro, high-fat diet in vivo model, PCSK9 secretion measurement","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic knockouts with pathway dissection; single lab","pmids":["32641981"],"is_preprint":false},{"year":2021,"finding":"LRP5 forms a physical complex with PCSK9 in lipid-loaded macrophages, and both contribute to macrophage lipid uptake. In the absence of both LRP5 and PCSK9, cholesterol ester accumulation is strongly reduced. LRP5 silencing also reduces soluble PCSK9 release, indicating LRP5 participates in PCSK9 secretion. PCSK9 upregulates TLR4/NF-κB signaling in macrophages after lipid loading.","method":"Co-immunoprecipitation, siRNA knockdown of LRP5 and PCSK9 in primary human macrophages, cholesterol ester accumulation assay, NF-κB nuclear translocation assay","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP plus siRNA functional assay; single lab, moderate mechanistic depth","pmids":["32991689"],"is_preprint":false},{"year":2022,"finding":"Adenylyl cyclase-associated protein 1 (CAP1) is identified as the main cell-surface binding partner of PCSK9 in macrophages, mediating LDLR-independent pro-inflammatory signaling. PCSK9-CAP1 binding activates spleen tyrosine kinase (Syk) and PKCδ, leading to NF-κB activation and upregulation of TLR4, scavenger receptors, and pro-inflammatory cytokines. In LDLR-knockout mice, AAV-mediated PCSK9 overexpression promotes vein graft lesion development without altering cholesterol levels.","method":"Systems biology/transcriptomics, in vitro stimulation of LDLR−/− macrophages with recombinant PCSK9, AAV gain-of-function in Ldlr−/− mice, in vivo molecular imaging, unbiased network analysis identifying CAP1, functional validation with CAP1-Fc fragment","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — LDLR-independent in vivo model combined with unbiased transcriptomics, binding partner identification, and kinase pathway validation with functional antagonism; multiple orthogonal methods","pmids":["38555386"],"is_preprint":false},{"year":2022,"finding":"The C-terminal Cys/His-rich domain (CHRD) of PCSK9 is required (in addition to catalytic domain binding to EGF-A of LDLR) for PCSK9 function; CHRD binds the secreted cytosolic cyclase associated protein 1 (CAP1), and this interaction is necessary for PCSK9-mediated LDLR degradation.","method":"Structural and biochemical analyses, domain-deletion studies, binding assays cited in review with primary data","journal":"Endocrine reviews","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multi-domain functional dissection cited across multiple studies; review paper summarizing primary data","pmids":["35552680"],"is_preprint":false},{"year":2025,"finding":"PCSK9 prevents the acidic pH-induced conformational change in the LDLR extracellular domain that is required for LDLR interaction with SNX17 (sorting nexin 17) via the LDLR intracellular domain. SNX17 is required for LDLR recycling; knocking down SNX17 abolishes LDLR recycling and causes lysosomal degradation. PCSK9 blocks SNX17 binding to LDLR, thereby diverting LDLR to lysosomal degradation. FH-associated sequence variations that disrupt LDLR recycling are unresponsive to PCSK9 or PCSK9 inhibitors.","method":"SNX17 knockdown in cells and in vivo, LDLR knockout HuH7 cells and mice reconstituted with FH variants, conformational assays, co-immunoprecipitation of LDLR-SNX17 interaction at neutral vs. acidic pH, PCSK9 binding assays","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 1 / Strong — mechanistic reconstitution in vitro and in vivo with SNX17 knockdown epistasis, pH-dependent conformational assays, and FH variant functional testing; multiple orthogonal approaches in one study","pmids":["40071387"],"is_preprint":false},{"year":2024,"finding":"PCSK9 inhibition in hepatocytes enhances the nuclear expression of PPARα by diminishing its lysosomal degradation, which subsequently activates CYP7A1 transcription and increases conversion of cholesterol to bile acids, preventing cholesterol gallstone formation in mice.","method":"In vitro PCSK9 inhibition in hepatocytes, nuclear/cytosolic fractionation for PPARα, PPARα lysosomal degradation assay, CYP7A1 promoter-reporter assay, CGS mouse model with alirocumab treatment","journal":"Metabolism: clinical and experimental","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic cell-based pathway dissection plus in vivo mouse model; single lab","pmids":["38191052"],"is_preprint":false},{"year":2025,"finding":"PCSK9 expression level in pancreatic ductal adenocarcinoma cells determines metastatic organ preference: PCSK9-low cells preferentially colonize the LDL-rich liver (importing LDL-cholesterol to activate mTORC1 and generate signaling oxysterol 24(S)-hydroxycholesterol), whereas PCSK9-high cells colonize the lung by upregulating distal cholesterol synthesis intermediates (7-dehydrocholesterol, 7-dehydrodesmosterol) that protect against ferroptosis. Increasing PCSK9 redirects liver-avid cells to the lung; ablating PCSK9 drives lung-avid cells to the liver.","method":"In vivo mouse metastasis modeling, gene expression correlation analysis, PCSK9 overexpression and genetic ablation in PDAC cell lines, mTORC1 activity assays, oxysterol quantification, ferroptosis assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — gain- and loss-of-function in vivo with mechanistic metabolic pathway dissection; multiple orthogonal methods, single study","pmids":["40399683"],"is_preprint":false},{"year":2009,"finding":"Annexin A2 specifically binds the C-terminal Cys/His-rich domain (CHRD) of PCSK9 and inhibits its function on LDLR degradation, identifying CHRD as a functional domain and Annexin A2 as an endogenous inhibitor.","method":"Binding assays, PCSK9 domain mapping, LDLR degradation assay with Annexin A2","journal":"Expert opinion on therapeutic targets","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — binding domain identification with functional inhibition assay; cited as established finding across multiple reviews","pmids":["19063703"],"is_preprint":false},{"year":2014,"finding":"Circulating PCSK9 binds to apolipoprotein B100 on LDL particles, which inhibits PCSK9's ability to bind to cell surface LDLRs, providing a negative feedback mechanism on PCSK9 activity.","method":"Biochemical binding assays (PCSK9-LDL interaction), LDLR binding competition assays","journal":"Current opinion in lipidology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — binding assay data summarized in review; single experimental approach","pmids":["25110901"],"is_preprint":false}],"current_model":"PCSK9 is a secreted serine protease that undergoes autocatalytic ER processing of its prosegment; once secreted, it binds via its catalytic domain to the EGF-A domain of LDLR at the hepatocyte surface, is co-internalized by clathrin-mediated endocytosis, and at acidic endosomal pH exploits an additional electrostatic interaction between its C-terminal CHRD and the LDLR ligand-binding domain to prevent LDLR from adopting the closed conformation needed for recycling and from interacting with the recycling adaptor SNX17, thereby diverting LDLR to lysosomal degradation in a non-enzymatic (chaperone) fashion; beyond LDLR, PCSK9 also promotes lysosomal degradation of MHC-I and other receptors, activates LDLR-independent inflammatory signaling through a CAP1–Syk–PKCδ–NF-κB axis, and its expression level in cancer cells governs cholesterol metabolic reprogramming that dictates metastatic organ tropism."},"narrative":{"mechanistic_narrative":"PCSK9 is a secreted proteinase K-like subtilase that governs LDL cholesterol metabolism by controlling the surface abundance of the LDL receptor (LDLR), and human gain-of-function mutations (S127R, D374Y) in PCSK9 cause autosomal dominant hypercholesterolemia [PMID:12730697]. The protein matures by Ca2+-independent autocatalytic intramolecular cleavage of its prosegment at an (Y,I)VV(V,L)(L,M) motif in the ER, with hydrophobic residues at P1/P3/P5 critical for recognition, after which the mature convertase is secreted [PMID:12552133, PMID:15358785, PMID:14622975]. Its proteolytic activity is dispensable for LDLR regulation: instead PCSK9 acts as a chaperone, binding LDLR and routing it to lysosomal degradation rather than recycling [PMID:15358785, PMID:18649882]. Mechanistically, the PCSK9 catalytic domain engages the EGF-A domain of LDLR at the cell surface; after clathrin-mediated co-internalization, an acidic-pH electrostatic interaction with the LDLR ligand-binding domain holds the complex together and blocks the conformational change LDLR needs to recycle [PMID:25222343], specifically preventing LDLR from binding the recycling adaptor SNX17 and thereby diverting it to lysosomal destruction [PMID:40071387]. The C-terminal Cys/His-rich domain (CHRD) is a second functional module required for full activity; it is bound and inhibited by Annexin A2 and engages CAP1 in support of LDLR degradation [PMID:35552680, PMID:19063703]. Beyond LDLR, PCSK9 drives lysosomal degradation of MHC class I on tumor cells, dampening cytotoxic T-cell infiltration so that its blockade potentiates anti-PD1 therapy [PMID:33177715], and it activates LDLR-independent pro-inflammatory signaling through cell-surface CAP1, triggering a Syk–PKCδ–NF-κB axis that upregulates TLR4, scavenger receptors, and cytokines [PMID:38555386]. PCSK9 secretion is itself induced by NLRP3 inflammasome/IL-1β signaling [PMID:32641981], and its expression level in pancreatic cancer cells reprograms cholesterol metabolism to dictate metastatic organ tropism between liver and lung [PMID:40399683].","teleology":[{"year":2003,"claim":"Established the enzymatic identity of PCSK9, answering how the newly identified protein matures and what cleavage specificity governs its zymogen processing.","evidence":"Biosynthetic analysis, microsequencing, in vitro peptide processing, and Ala-scanning across P1-P5 of recombinant enzyme","pmids":["12552133","14622975"],"confidence":"High","gaps":["Did not identify physiological substrates beyond the prosegment","Did not connect the protease activity to a cellular function"]},{"year":2003,"claim":"Connected PCSK9 to human disease, answering whether the protein has a physiological role in lipid homeostasis by linking specific mutations to hypercholesterolemia.","evidence":"Linkage mapping and mutation identification in autosomal dominant hypercholesterolemia kindreds","pmids":["12730697"],"confidence":"High","gaps":["Did not establish the molecular mechanism by which mutations raise LDL","Did not distinguish gain- versus loss-of-function consequences mechanistically"]},{"year":2003,"claim":"Showed PCSK9 acts on the LDLR and operates in vivo, answering whether PCSK9 controls LDL by degrading the receptor and whether the effect is LDLR-dependent.","evidence":"Stable HepG2 overexpression with ammonium chloride inhibition, adenoviral hepatic overexpression in WT and LDLR-/- mice, and characterization of mutant zymogen processing","pmids":["15358785"],"confidence":"High","gaps":["Did not resolve whether catalytic activity was required for LDLR loss","The LDLR-independent ~2-fold effect in LDLR-/- mice was unexplained"]},{"year":2003,"claim":"Localized the maturation and trafficking of PCSK9, addressing where processing occurs and how the secreted protein intersects the LDLR endocytic route.","evidence":"Subcellular fractionation and confocal double-immunofluorescence with LDLR and clathrin antibodies","pmids":["16462892"],"confidence":"Medium","gaps":["Colocalization was partial and correlative","Did not demonstrate direct co-trafficking of a PCSK9-LDLR complex"]},{"year":2006,"claim":"Probed non-hepatic roles, testing whether PCSK9 has functions outside cholesterol metabolism in the nervous system.","evidence":"Morpholino knockdown in zebrafish with neuroanatomical phenotyping, and overexpression with active-site/deletion mutants in primary cerebellar granule neurons","pmids":["16893422","17051583"],"confidence":"Medium","gaps":["Morpholino specificity and off-target effects not fully excluded","Mechanistic link between protease activity and neuronal apoptosis not defined","Relevance to mammalian CNS unestablished"]},{"year":2008,"claim":"Resolved the central mechanistic question of whether PCSK9 needs its protease activity, establishing that it acts as a non-enzymatic chaperone for LDLR degradation.","evidence":"Catalytic-site mutagenesis combined with crystal structure determination and LDLR degradation assays","pmids":["18649882"],"confidence":"High","gaps":["Did not define the endosomal trafficking step that commits LDLR to lysosomes","Did not explain how the complex evades recycling"]},{"year":2009,"claim":"Identified the CHRD as a functional domain and an endogenous regulator, addressing how PCSK9 activity can be modulated post-secretion.","evidence":"Domain mapping and binding assays with Annexin A2, plus LDLR degradation assays","pmids":["19063703"],"confidence":"Medium","gaps":["Structural basis of Annexin A2-CHRD binding not resolved","Physiological extent of Annexin A2 regulation in vivo unquantified"]},{"year":2014,"claim":"Assembled the molecular model of how PCSK9 traps LDLR, answering how a surface-binding event is converted into lysosomal diversion and how circulating PCSK9 is buffered.","evidence":"Mechanistic synthesis of structural/biochemical data on EGF-A binding and acidic-pH C-terminal interaction; biochemical apoB100-PCSK9 binding and LDLR competition assays","pmids":["25222343","25110901"],"confidence":"High","gaps":["Identity of the recycling-blocking adaptor not yet defined","In vivo relevance of the apoB100 feedback not quantified"]},{"year":2015,"claim":"Extended PCSK9 into vascular inflammation, addressing whether PCSK9 participates in atherogenic signaling independent of hepatic lipid handling.","evidence":"Reciprocal siRNA/overexpression and LOX-1 and PCSK9 knockout mice with mtROS manipulation; NF-kB/VCAM-1 readouts","pmids":["26092101"],"confidence":"Medium","gaps":["Direct physical interaction not demonstrated","Causal direction of the LOX-1/PCSK9 loop incompletely resolved"]},{"year":2020,"claim":"Defined an immune function for PCSK9, answering whether it regulates antigen presentation and could be leveraged in cancer immunotherapy.","evidence":"Co-immunoprecipitation, PCSK9 deletion and neutralizing antibody in syngeneic tumors, MHC-I flow cytometry, and T-cell depletion epistasis","pmids":["33177715"],"confidence":"High","gaps":["Domain of PCSK9 mediating MHC-I binding not mapped","Whether MHC-I degradation uses the same trafficking machinery as LDLR unknown"]},{"year":2020,"claim":"Identified an upstream regulator of PCSK9 release, addressing how inflammation controls PCSK9 levels.","evidence":"NLRP3, IL-1b, IL-18 and caspase-1 knockout mice, macrophages, and high-fat diet model measuring PCSK9 secretion","pmids":["32641981"],"confidence":"Medium","gaps":["Mechanism by which IL-1b drives secretion not defined","Tissue source contributions not fully separated"]},{"year":2021,"claim":"Linked PCSK9 to macrophage lipid uptake and secretion, addressing partners that act with PCSK9 in foam-cell formation.","evidence":"Co-IP and siRNA of LRP5 and PCSK9 in primary human macrophages with cholesterol ester and NF-kB assays","pmids":["32991689"],"confidence":"Medium","gaps":["Single-lab Co-IP without structural mapping","Whether LRP5 is a PCSK9 degradation substrate or a secretion cofactor unresolved"]},{"year":2022,"claim":"Identified the receptor for LDLR-independent inflammatory signaling, answering how secreted PCSK9 transmits a pro-inflammatory signal at the cell surface.","evidence":"Unbiased transcriptomics, recombinant PCSK9 stimulation of LDLR-/- macrophages, CAP1 identification with CAP1-Fc antagonism, and AAV PCSK9 in Ldlr-/- mice with molecular imaging","pmids":["38555386"],"confidence":"High","gaps":["Structural basis of PCSK9-CAP1 engagement not solved","How CAP1 couples to Syk activation mechanistically unclear"]},{"year":2022,"claim":"Connected the CHRD to CAP1 in LDLR degradation, addressing the role of the second PCSK9 domain in receptor turnover.","evidence":"Domain-deletion and binding studies summarized with primary data","pmids":["35552680"],"confidence":"Medium","gaps":["Review-level synthesis rather than single primary dataset","Quantitative contribution of CHRD-CAP1 versus catalytic-EGF-A binding not separated"]},{"year":2024,"claim":"Revealed a hepatic bile-acid axis controlled by PCSK9, addressing downstream metabolic consequences of PCSK9 inhibition.","evidence":"Hepatocyte PCSK9 inhibition, PPARa nuclear/lysosomal fractionation, CYP7A1 promoter-reporter, and gallstone mouse model with alirocumab","pmids":["38191052"],"confidence":"Medium","gaps":["Whether PCSK9 directly degrades PPARa or acts indirectly unresolved","Single-lab in vivo model"]},{"year":2025,"claim":"Pinpointed the recycling step PCSK9 blocks, answering precisely how PCSK9 converts endosomal LDLR from recycling to degradation.","evidence":"SNX17 knockdown in cells and in vivo, LDLR-/- HuH7 cells and mice reconstituted with FH variants, pH-dependent conformational and co-IP assays","pmids":["40071387"],"confidence":"High","gaps":["Structure of the LDLR-SNX17 interface not solved","Why some FH variants are intrinsically PCSK9-unresponsive at atomic detail unclear"]},{"year":2025,"claim":"Established PCSK9 as a determinant of cancer metastatic tropism, addressing how PCSK9 expression reprograms cholesterol metabolism to dictate organ colonization.","evidence":"In vivo PDAC metastasis modeling with PCSK9 overexpression/ablation, mTORC1 assays, oxysterol quantification, and ferroptosis assays","pmids":["40399683"],"confidence":"High","gaps":["Whether tropism control depends on secreted versus intracellular PCSK9 unresolved","Generalizability beyond pancreatic cancer untested"]},{"year":null,"claim":"How PCSK9 selects and traffics its non-LDLR targets (MHC-I and other receptors) and whether a single structural mechanism unifies its chaperone, inflammatory, and metabolic-reprogramming functions remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No shared structural model linking LDLR, MHC-I, and CAP1 engagement","Domain requirements for non-LDLR cargo degradation unmapped","Relative in vivo contribution of intracellular versus secreted PCSK9 to each function unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,6]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,6]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[9,10,17]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[15]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[4,5]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[5]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[10,17]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[3,10,12]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[10,15]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,4,19]},{"term_id":"R-HSA-9609507","term_label":"Protein localization","supporting_discovery_ids":[10,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[12,13,15]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[15]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,9]}],"complexes":[],"partners":["LDLR","CAP1","MHC CLASS I","ANXA2","LRP5","SNX17","APOB","LOX-1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8NBP7","full_name":"Proprotein convertase subtilisin/kexin type 9","aliases":["Neural apoptosis-regulated convertase 1","NARC-1","Proprotein convertase 9","PC9","Subtilisin/kexin-like protease PC9"],"length_aa":692,"mass_kda":74.3,"function":"Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:17461796, PubMed:18197702, PubMed:18799458, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways","subcellular_location":"Cytoplasm; Secreted; Endosome; Lysosome; Cell surface; Endoplasmic reticulum; Golgi apparatus","url":"https://www.uniprot.org/uniprotkb/Q8NBP7/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PCSK9","classification":"Not Classified","n_dependent_lines":62,"n_total_lines":1208,"dependency_fraction":0.05132450331125828},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PCSK9","total_profiled":1310},"omim":[{"mim_id":"618666","title":"SITOSTEROLEMIA 2; STSL2","url":"https://www.omim.org/entry/618666"},{"mim_id":"613589","title":"LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 6; LDLCQ6","url":"https://www.omim.org/entry/613589"},{"mim_id":"607786","title":"PROPROTEIN CONVERTASE, SUBTILISIN/KEXIN-TYPE, 9; PCSK9","url":"https://www.omim.org/entry/607786"},{"mim_id":"606945","title":"LOW DENSITY LIPOPROTEIN RECEPTOR; LDLR","url":"https://www.omim.org/entry/606945"},{"mim_id":"605460","title":"ATP-BINDING CASSETTE, SUBFAMILY G, MEMBER 8; ABCG8","url":"https://www.omim.org/entry/605460"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"liver","ntpm":47.5}],"url":"https://www.proteinatlas.org/search/PCSK9"},"hgnc":{"alias_symbol":["NARC-1","FH3"],"prev_symbol":["HCHOLA3"]},"alphafold":{"accession":"Q8NBP7","domains":[{"cath_id":"3.30.70.80","chopping":"64-147","consensus_level":"high","plddt":97.0756,"start":64,"end":147},{"cath_id":"3.40.50.200","chopping":"153-166_177-211_224-442","consensus_level":"high","plddt":92.1246,"start":153,"end":442},{"cath_id":"2.60.120.690","chopping":"457-568_579-682","consensus_level":"high","plddt":89.3681,"start":457,"end":682}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8NBP7","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8NBP7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8NBP7-F1-predicted_aligned_error_v6.png","plddt_mean":85.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PCSK9","jax_strain_url":"https://www.jax.org/strain/search?query=PCSK9"},"sequence":{"accession":"Q8NBP7","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8NBP7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8NBP7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8NBP7"}},"corpus_meta":[{"pmid":"12730697","id":"PMC_12730697","title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12730697","citation_count":2308,"is_preprint":false},{"pmid":"12552133","id":"PMC_12552133","title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12552133","citation_count":989,"is_preprint":false},{"pmid":"27959715","id":"PMC_27959715","title":"A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.","date":"2016","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27959715","citation_count":601,"is_preprint":false},{"pmid":"15358785","id":"PMC_15358785","title":"NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15358785","citation_count":541,"is_preprint":false},{"pmid":"24625727","id":"PMC_24625727","title":"PCSK9: a key modulator of cardiovascular health.","date":"2014","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/24625727","citation_count":492,"is_preprint":false},{"pmid":"33177715","id":"PMC_33177715","title":"Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33177715","citation_count":387,"is_preprint":false},{"pmid":"22811413","id":"PMC_22811413","title":"The PCSK9 decade.","date":"2012","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/22811413","citation_count":369,"is_preprint":false},{"pmid":"25110901","id":"PMC_25110901","title":"PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.","date":"2014","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/25110901","citation_count":286,"is_preprint":false},{"pmid":"30420622","id":"PMC_30420622","title":"PCSK9 inhibitors: clinical evidence and implementation.","date":"2019","source":"Nature reviews. Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/30420622","citation_count":264,"is_preprint":false},{"pmid":"26092101","id":"PMC_26092101","title":"Cross-talk between LOX-1 and PCSK9 in vascular tissues.","date":"2015","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/26092101","citation_count":205,"is_preprint":false},{"pmid":"35552680","id":"PMC_35552680","title":"The Multifaceted Biology of PCSK9.","date":"2022","source":"Endocrine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/35552680","citation_count":184,"is_preprint":false},{"pmid":"24958078","id":"PMC_24958078","title":"Lipid lowering with PCSK9 inhibitors.","date":"2014","source":"Nature reviews. Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/24958078","citation_count":178,"is_preprint":false},{"pmid":"31236571","id":"PMC_31236571","title":"PCSK9 and inflammation: a review of experimental and clinical evidence.","date":"2019","source":"European heart journal. Cardiovascular pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/31236571","citation_count":172,"is_preprint":false},{"pmid":"18649882","id":"PMC_18649882","title":"Molecular basis of PCSK9 function.","date":"2008","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/18649882","citation_count":164,"is_preprint":false},{"pmid":"34070931","id":"PMC_34070931","title":"PCSK9 Biology and Its Role in Atherothrombosis.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34070931","citation_count":135,"is_preprint":false},{"pmid":"21596380","id":"PMC_21596380","title":"Clinical aspects of PCSK9.","date":"2011","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/21596380","citation_count":133,"is_preprint":false},{"pmid":"14622975","id":"PMC_14622975","title":"Functional characterization of Narc 1, a novel proteinase related to proteinase K.","date":"2003","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/14622975","citation_count":132,"is_preprint":false},{"pmid":"38185721","id":"PMC_38185721","title":"Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside.","date":"2024","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38185721","citation_count":127,"is_preprint":false},{"pmid":"30367179","id":"PMC_30367179","title":"Inhibiting PCSK9 - biology beyond LDL control.","date":"2018","source":"Nature reviews. Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30367179","citation_count":119,"is_preprint":false},{"pmid":"31524223","id":"PMC_31524223","title":"Quercetin protects against atherosclerosis by regulating the expression of PCSK9, CD36, PPARγ, LXRα and ABCA1.","date":"2019","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31524223","citation_count":118,"is_preprint":false},{"pmid":"19063703","id":"PMC_19063703","title":"PCSK9 as a therapeutic target of dyslipidemia.","date":"2009","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/19063703","citation_count":112,"is_preprint":false},{"pmid":"28363723","id":"PMC_28363723","title":"Regulation of PCSK9 by nutraceuticals.","date":"2017","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/28363723","citation_count":107,"is_preprint":false},{"pmid":"37331523","id":"PMC_37331523","title":"Targeting PCSK9 to tackle cardiovascular disease.","date":"2023","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/37331523","citation_count":106,"is_preprint":false},{"pmid":"29353350","id":"PMC_29353350","title":"Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor.","date":"2018","source":"Clinical pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/29353350","citation_count":103,"is_preprint":false},{"pmid":"16893422","id":"PMC_16893422","title":"Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system.","date":"2006","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16893422","citation_count":102,"is_preprint":false},{"pmid":"28804094","id":"PMC_28804094","title":"Lipid Lowering Therapy and Circulating PCSK9 Concentration.","date":"2017","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/28804094","citation_count":100,"is_preprint":false},{"pmid":"31404822","id":"PMC_31404822","title":"PCSK9 inhibition and inflammation: A narrative review.","date":"2019","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/31404822","citation_count":99,"is_preprint":false},{"pmid":"24160703","id":"PMC_24160703","title":"Targeting PCSK9 for hypercholesterolemia.","date":"2013","source":"Annual review of pharmacology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/24160703","citation_count":94,"is_preprint":false},{"pmid":"34782856","id":"PMC_34782856","title":"Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications.","date":"2021","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34782856","citation_count":90,"is_preprint":false},{"pmid":"34058443","id":"PMC_34058443","title":"PCSK9 and cancer: Rethinking the link.","date":"2021","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/34058443","citation_count":83,"is_preprint":false},{"pmid":"36230934","id":"PMC_36230934","title":"PCSK9 Inhibition: From Current Advances to Evolving Future.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36230934","citation_count":82,"is_preprint":false},{"pmid":"32713931","id":"PMC_32713931","title":"An Update on the Role of PCSK9 in Atherosclerosis.","date":"2020","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/32713931","citation_count":81,"is_preprint":false},{"pmid":"28970592","id":"PMC_28970592","title":"A Therapeutic Peptide Vaccine Against PCSK9.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28970592","citation_count":77,"is_preprint":false},{"pmid":"28439730","id":"PMC_28439730","title":"Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.","date":"2017","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/28439730","citation_count":77,"is_preprint":false},{"pmid":"33236356","id":"PMC_33236356","title":"PCSK9 and atherosclerosis: Looking beyond LDL regulation.","date":"2020","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33236356","citation_count":73,"is_preprint":false},{"pmid":"32991689","id":"PMC_32991689","title":"PCSK9 and LRP5 in macrophage lipid internalization and inflammation.","date":"2021","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/32991689","citation_count":73,"is_preprint":false},{"pmid":"35593194","id":"PMC_35593194","title":"A Comprehensive Review of PCSK9 Inhibitors.","date":"2022","source":"Journal of cardiovascular pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/35593194","citation_count":72,"is_preprint":false},{"pmid":"35048716","id":"PMC_35048716","title":"Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis.","date":"2022","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/35048716","citation_count":72,"is_preprint":false},{"pmid":"25887680","id":"PMC_25887680","title":"Role of PCSK9 beyond liver involvement.","date":"2015","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/25887680","citation_count":71,"is_preprint":false},{"pmid":"25222343","id":"PMC_25222343","title":"Sorting an LDL receptor with bound PCSK9 to intracellular degradation.","date":"2014","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/25222343","citation_count":71,"is_preprint":false},{"pmid":"30207556","id":"PMC_30207556","title":"PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety.","date":"2018","source":"Reviews in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30207556","citation_count":70,"is_preprint":false},{"pmid":"24373748","id":"PMC_24373748","title":"PCSK9: From discovery to therapeutic applications.","date":"2013","source":"Archives of cardiovascular diseases","url":"https://pubmed.ncbi.nlm.nih.gov/24373748","citation_count":70,"is_preprint":false},{"pmid":"30605918","id":"PMC_30605918","title":"PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention.","date":"2019","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/30605918","citation_count":68,"is_preprint":false},{"pmid":"32641981","id":"PMC_32641981","title":"NLRP3 inflammasome via IL-1β regulates PCSK9 secretion.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/32641981","citation_count":67,"is_preprint":false},{"pmid":"36263780","id":"PMC_36263780","title":"Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms.","date":"2022","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/36263780","citation_count":66,"is_preprint":false},{"pmid":"28302950","id":"PMC_28302950","title":"PCSK9 and Atherosclerosis - Lipids and Beyond.","date":"2017","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/28302950","citation_count":64,"is_preprint":false},{"pmid":"33304274","id":"PMC_33304274","title":"PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects.","date":"2020","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33304274","citation_count":63,"is_preprint":false},{"pmid":"28587771","id":"PMC_28587771","title":"Hypercholesterolemia: The role of PCSK9.","date":"2017","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/28587771","citation_count":62,"is_preprint":false},{"pmid":"35904732","id":"PMC_35904732","title":"Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond.","date":"2022","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/35904732","citation_count":62,"is_preprint":false},{"pmid":"28784313","id":"PMC_28784313","title":"PCSK9 inhibition in the management of familial hypercholesterolemia.","date":"2017","source":"Journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/28784313","citation_count":62,"is_preprint":false},{"pmid":"18663786","id":"PMC_18663786","title":"PCSK9 function and physiology.","date":"2008","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/18663786","citation_count":61,"is_preprint":false},{"pmid":"28063230","id":"PMC_28063230","title":"PCSK9 at the crossroad of cholesterol metabolism and immune function during infections.","date":"2017","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28063230","citation_count":60,"is_preprint":false},{"pmid":"27575716","id":"PMC_27575716","title":"PCSK9: Regulation and Target for Drug Development for Dyslipidemia.","date":"2016","source":"Annual review of pharmacology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/27575716","citation_count":56,"is_preprint":false},{"pmid":"30246446","id":"PMC_30246446","title":"PCSK9: A novel inflammation modulator in atherosclerosis?","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30246446","citation_count":54,"is_preprint":false},{"pmid":"29758414","id":"PMC_29758414","title":"Role of PCSK9 in lipid metabolism and atherosclerosis.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/29758414","citation_count":54,"is_preprint":false},{"pmid":"17051583","id":"PMC_17051583","title":"Proapoptotic effects of NARC 1 (= PCSK9), the gene encoding a novel serine proteinase.","date":"2006","source":"Cytometry. Part A : the journal of the International Society for Analytical Cytology","url":"https://pubmed.ncbi.nlm.nih.gov/17051583","citation_count":51,"is_preprint":false},{"pmid":"34356856","id":"PMC_34356856","title":"PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology.","date":"2021","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/34356856","citation_count":50,"is_preprint":false},{"pmid":"34144130","id":"PMC_34144130","title":"Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer.","date":"2021","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34144130","citation_count":50,"is_preprint":false},{"pmid":"27315084","id":"PMC_27315084","title":"Statins and Their Effect on PCSK9-Impact and Clinical Relevance.","date":"2016","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/27315084","citation_count":48,"is_preprint":false},{"pmid":"37284459","id":"PMC_37284459","title":"PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging.","date":"2023","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/37284459","citation_count":47,"is_preprint":false},{"pmid":"28111330","id":"PMC_28111330","title":"PCSK9 and diabetes: is there a link?","date":"2017","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/28111330","citation_count":47,"is_preprint":false},{"pmid":"26987067","id":"PMC_26987067","title":"Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?","date":"2016","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/26987067","citation_count":47,"is_preprint":false},{"pmid":"18280815","id":"PMC_18280815","title":"PCSK9: an enigmatic protease.","date":"2008","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/18280815","citation_count":46,"is_preprint":false},{"pmid":"32495301","id":"PMC_32495301","title":"New Pharmacological Approaches to Target PCSK9.","date":"2020","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/32495301","citation_count":46,"is_preprint":false},{"pmid":"36411665","id":"PMC_36411665","title":"Safety of PCSK9 inhibitors.","date":"2022","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36411665","citation_count":46,"is_preprint":false},{"pmid":"38555386","id":"PMC_38555386","title":"PCSK9 stimulates Syk, PKCδ, and NF-κB, leading to atherosclerosis progression independently of LDL receptor.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38555386","citation_count":45,"is_preprint":false},{"pmid":"33119548","id":"PMC_33119548","title":"microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/33119548","citation_count":45,"is_preprint":false},{"pmid":"33808697","id":"PMC_33808697","title":"Pleiotropic Effects of PCSK-9 Inhibitors.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33808697","citation_count":43,"is_preprint":false},{"pmid":"33335431","id":"PMC_33335431","title":"Safety and Tolerability of PCSK9 Inhibitors: Current Insights.","date":"2020","source":"Clinical pharmacology : advances and applications","url":"https://pubmed.ncbi.nlm.nih.gov/33335431","citation_count":42,"is_preprint":false},{"pmid":"28084558","id":"PMC_28084558","title":"PCSK9 in chronic kidney disease.","date":"2017","source":"International urology and nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/28084558","citation_count":41,"is_preprint":false},{"pmid":"32875580","id":"PMC_32875580","title":"Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32875580","citation_count":41,"is_preprint":false},{"pmid":"28176216","id":"PMC_28176216","title":"PCSK9 targets important for lipid metabolism.","date":"2017","source":"Clinical research in cardiology supplements","url":"https://pubmed.ncbi.nlm.nih.gov/28176216","citation_count":40,"is_preprint":false},{"pmid":"23652470","id":"PMC_23652470","title":"PCSK9 inhibitors.","date":"2013","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/23652470","citation_count":39,"is_preprint":false},{"pmid":"30318062","id":"PMC_30318062","title":"PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?","date":"2018","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/30318062","citation_count":39,"is_preprint":false},{"pmid":"30522786","id":"PMC_30522786","title":"PCSK9: from biology to clinical applications.","date":"2018","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30522786","citation_count":38,"is_preprint":false},{"pmid":"28179493","id":"PMC_28179493","title":"Nutritional and Lipid Modulation of PCSK9: Effects on Cardiometabolic Risk Factors.","date":"2017","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/28179493","citation_count":37,"is_preprint":false},{"pmid":"29665987","id":"PMC_29665987","title":"Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?","date":"2018","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/29665987","citation_count":36,"is_preprint":false},{"pmid":"25410128","id":"PMC_25410128","title":"PCSK9: A key factor modulating atherosclerosis.","date":"2014","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/25410128","citation_count":35,"is_preprint":false},{"pmid":"30395847","id":"PMC_30395847","title":"Potentiation of Psoriasis-Like Inflammation by PCSK9.","date":"2018","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/30395847","citation_count":34,"is_preprint":false},{"pmid":"36535197","id":"PMC_36535197","title":"PCSK9: A emerging participant in heart failure.","date":"2022","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36535197","citation_count":34,"is_preprint":false},{"pmid":"24407047","id":"PMC_24407047","title":"Antihyperlipidemic therapies targeting PCSK9.","date":"2014","source":"Cardiology in review","url":"https://pubmed.ncbi.nlm.nih.gov/24407047","citation_count":34,"is_preprint":false},{"pmid":"40071387","id":"PMC_40071387","title":"PCSK9 Promotes LDLR Degradation by Preventing SNX17-Mediated LDLR Recycling.","date":"2025","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/40071387","citation_count":33,"is_preprint":false},{"pmid":"40399683","id":"PMC_40399683","title":"PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer.","date":"2025","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/40399683","citation_count":32,"is_preprint":false},{"pmid":"39547595","id":"PMC_39547595","title":"PCSK9 in metabolism and diseases.","date":"2024","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/39547595","citation_count":32,"is_preprint":false},{"pmid":"35135698","id":"PMC_35135698","title":"PCSK9 promotes arterial medial calcification.","date":"2022","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/35135698","citation_count":32,"is_preprint":false},{"pmid":"35050192","id":"PMC_35050192","title":"Gene Therapy Targeting PCSK9.","date":"2022","source":"Metabolites","url":"https://pubmed.ncbi.nlm.nih.gov/35050192","citation_count":31,"is_preprint":false},{"pmid":"32615123","id":"PMC_32615123","title":"Characterization of PCSK9 in the Blood and Skin of Psoriasis.","date":"2020","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/32615123","citation_count":31,"is_preprint":false},{"pmid":"37059376","id":"PMC_37059376","title":"The evolving landscape of PCSK9 inhibition in cancer.","date":"2023","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37059376","citation_count":31,"is_preprint":false},{"pmid":"26320603","id":"PMC_26320603","title":"PCSK9 and triglyceride-rich lipoprotein metabolism.","date":"2015","source":"Journal of biomedical research","url":"https://pubmed.ncbi.nlm.nih.gov/26320603","citation_count":30,"is_preprint":false},{"pmid":"34928185","id":"PMC_34928185","title":"The role of PCSK9 in inflammation, immunity, and autoimmune diseases.","date":"2021","source":"Expert review of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34928185","citation_count":30,"is_preprint":false},{"pmid":"16462892","id":"PMC_16462892","title":"Expression and localization of PCSK9 in rat hepatic cells.","date":"2006","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/16462892","citation_count":30,"is_preprint":false},{"pmid":"38191052","id":"PMC_38191052","title":"Inhibition of PCSK9 prevents and alleviates cholesterol gallstones through PPARα-mediated CYP7A1 activation.","date":"2024","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/38191052","citation_count":29,"is_preprint":false},{"pmid":"33307067","id":"PMC_33307067","title":"PCSK9: Associated with cardiac diseases and their risk factors?","date":"2020","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/33307067","citation_count":29,"is_preprint":false},{"pmid":"28574577","id":"PMC_28574577","title":"PCSK9 and infection: A potentially useful or dangerous association?","date":"2017","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28574577","citation_count":29,"is_preprint":false},{"pmid":"37586604","id":"PMC_37586604","title":"PCSK9 and the nervous system: a no-brainer?","date":"2023","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/37586604","citation_count":28,"is_preprint":false},{"pmid":"29428206","id":"PMC_29428206","title":"Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps.","date":"2018","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/29428206","citation_count":28,"is_preprint":false},{"pmid":"37019248","id":"PMC_37019248","title":"Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system.","date":"2023","source":"Neuroscience and biobehavioral reviews","url":"https://pubmed.ncbi.nlm.nih.gov/37019248","citation_count":28,"is_preprint":false},{"pmid":"37967665","id":"PMC_37967665","title":"PCSK9 ablation attenuates Aβ pathology, neuroinflammation and cognitive dysfunctions in 5XFAD mice.","date":"2023","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/37967665","citation_count":27,"is_preprint":false},{"pmid":"25444750","id":"PMC_25444750","title":"PCSK9 and its modulation.","date":"2014","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25444750","citation_count":27,"is_preprint":false},{"pmid":"25036764","id":"PMC_25036764","title":"PCSK9 and lipid lowering drugs.","date":"2014","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25036764","citation_count":27,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48544,"output_tokens":5724,"usd":0.115746,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14333,"output_tokens":5477,"usd":0.104295,"stage2_stop_reason":"end_turn"},"total_usd":0.220041,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"PCSK9 (NARC-1) is a proteinase K-like subtilase that undergoes autocatalytic intramolecular processing of its prosegment at the (Y,I)VV(V,L)(L,M) motif; in vitro peptide processing studies and Ala substitutions of P1–P5 sites established that hydrophobic/aliphatic residues are critical at P1, P3, and P5 for substrate recognition.\",\n      \"method\": \"Biosynthetic analysis, microsequencing of WT and mutant enzyme, in vitro peptide processing assays, Ala-scanning mutagenesis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution of autocatalytic processing combined with active-site mutagenesis in a dedicated mechanistic study\",\n      \"pmids\": [\"12552133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Gain-of-function mutations in PCSK9 (S127R and D374Y) cause autosomal dominant hypercholesterolemia, establishing PCSK9 as a genetic determinant of LDL cholesterol metabolism.\",\n      \"method\": \"Human genetic linkage mapping and mutation identification in ADH kindreds\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human genetics firmly linked PCSK9 mutations to hypercholesterolemia, replicated broadly\",\n      \"pmids\": [\"12730697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PCSK9 autocatalytic zymogen processing is Ca2+-independent; Val at P4 and Pro at P3′ are critical for processing at the SSVFAQ↓SIP site. Gain-of-function mutants S127R and D374Y reduce zymogen processing by ~50–60% and ≥98%, respectively, whereas F216L, R218S, and double D374Y+N157K mutants show normal processing.\",\n      \"method\": \"Biosynthetic analysis of WT and natural mutant NARC-1, site-directed mutagenesis, Ca2+-depletion experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro biochemical reconstitution with mutagenesis across multiple natural variants in a single study\",\n      \"pmids\": [\"15358785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Overexpression of NARC-1/PCSK9 in stable HepG2 cells reduces LDL receptor (LDLR) levels, an effect abrogated by ammonium chloride, indicating PCSK9 increases LDLR turnover via a lysosomal/endosomal pathway.\",\n      \"method\": \"Stable HepG2 cell overexpression, Western blot for LDLR, ammonium chloride inhibition of lysosomal degradation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-based loss/gain-of-function with pharmacological pathway dissection; replicated across multiple subsequent studies\",\n      \"pmids\": [\"15358785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Adenoviral expression of human NARC-1 in mice produces up to ~9-fold increase in circulating LDL cholesterol; in LDLR−/− mice a smaller ~2-fold delayed increase occurs, demonstrating both LDLR-dependent and LDLR-independent effects on LDL.\",\n      \"method\": \"Adenoviral hepatic overexpression in WT and LDLR−/− mice, plasma LDL measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic model with LDLR knockout epistasis cleanly separating LDLR-dependent from LDLR-independent effects\",\n      \"pmids\": [\"15358785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"NARC-1 autocatalytic processing occurs in the ER, and the mature convertase is secreted from liver and hepatoma cells; PCSK9 shows partial colocalization with clathrin-coated vesicles and LDLR by double immunofluorescence.\",\n      \"method\": \"Subcellular fractionation, Western blotting, confocal immunofluorescence double-labeling with LDLR and clathrin antibodies\",\n      \"journal\": \"Biochemistry and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by two orthogonal methods (fractionation + immunofluorescence), single lab\",\n      \"pmids\": [\"16462892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Rat Narc1 undergoes autocatalytic intramolecular processing at LVFAQ↓, generating an active protease with a broad alkaline pH optimum and no apparent calcium requirement; both primary and secondary structural determinants influence substrate recognition; the enzyme is classified in the proteinase K subfamily.\",\n      \"method\": \"Functional characterization: recombinant expression, prosegment cleavage assay, pH and calcium-dependence assays, substrate profiling\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical reconstitution with substrate and condition-dependence assays, single lab\",\n      \"pmids\": [\"14622975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Specific morpholino knockdown of zebrafish NARC-1/PCSK9 mRNA causes disorganization of cerebellar neurons and loss of hindbrain-midbrain boundaries leading to embryonic death, establishing a role for PCSK9 in CNS development distinct from its hepatic cholesterol function.\",\n      \"method\": \"Whole-mount in situ hybridization, morpholino-mediated knockdown in zebrafish, phenotypic analysis\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function in vivo model with specific neuroanatomical readout; single lab, zebrafish model\",\n      \"pmids\": [\"16893422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"NARC-1/PCSK9 overexpression in cerebellar granule neurons (CGNs) promotes caspase-dependent and caspase-independent apoptosis; mutation of the active-site serine or deletion of the catalytic domain reduces the BAF-sensitive (caspase-dependent) component of cell death, linking the protease activity to pro-apoptotic signaling.\",\n      \"method\": \"Transfection of EGFP-fusion constructs (WT, active-site mutant, deletion mutants) in primary CGNs; laser scanning cytometry-based cell death scoring; BAF (poly-caspase inhibitor) treatment\",\n      \"journal\": \"Cytometry Part A\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — active-site mutagenesis with functional cell death readout; single lab, single method platform\",\n      \"pmids\": [\"17051583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The enzymatic (protease) activity of PCSK9 is not required for LDLR degradation; instead, PCSK9 acts as a chaperone that binds LDLR and targets it for lysosomal degradation. This was demonstrated by site-directed mutagenesis of the catalytic site and crystal structure determination.\",\n      \"method\": \"Site-directed mutagenesis of catalytic site; crystal structure determination; LDLR degradation assays\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with catalytic-site mutagenesis, independently confirmed by multiple labs as reviewed\",\n      \"pmids\": [\"18649882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The catalytic domain of PCSK9 binds to the EGF-A domain of LDLR at the cell surface. Following clathrin-mediated endocytosis, an additional electrostatic interaction at acidic pH between the C-terminal domain of PCSK9 and the ligand-binding domain of LDLR keeps the complex intact in the sorting endosome, preventing LDLR from adopting a closed conformation required for recycling. LDLR ectodomain is subsequently cleaved by a cysteine cathepsin in the sorting endosome, directing it to lysosomal degradation.\",\n      \"method\": \"Literature synthesis of structural, biochemical, and cell biology studies; mechanistic model supported by referenced crystal structure and endosomal pH-dependence experiments\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mechanistic model supported by crystal structures and multiple independent labs' biochemical data as summarized in review\",\n      \"pmids\": [\"25222343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LOX-1 and PCSK9 positively regulate each other's expression in vascular endothelial and smooth muscle cells; siRNA knockdown of each reduces the other's expression, and LOX-1 KO mice show reduced PCSK9 and vice versa. Mitochondrial ROS (mtROS) acts as an upstream initiator of this crosstalk, and PCSK9 regulates VCAM-1 expression via NF-κB signaling.\",\n      \"method\": \"siRNA knockdown, cDNA overexpression, LOX-1 and PCSK9 knockout mice, mtROS inhibition/induction experiments\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal knockdown/overexpression with in vivo KO validation, single lab, two orthogonal approaches\",\n      \"pmids\": [\"26092101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PCSK9 physically associates with MHC class I proteins on tumor cell surfaces, promotes their relocation and lysosomal degradation, thereby reducing MHC-I cell surface expression; PCSK9 genetic deletion or antibody neutralization increases tumor cell surface MHC-I and enhances intratumoral cytotoxic T cell infiltration, potentiating anti-PD1 immune checkpoint therapy.\",\n      \"method\": \"Co-immunoprecipitation (physical association), PCSK9 gene deletion in mouse cancer cells, PCSK9 neutralizing antibodies, flow cytometry for MHC-I surface levels, T-cell depletion experiments, syngeneic mouse tumor models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP plus genetic KO plus antibody neutralization with in vivo tumor readout and T-cell epistasis; multiple orthogonal methods in one study\",\n      \"pmids\": [\"33177715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NLRP3 inflammasome and its downstream signals (ASC, Caspase-1, IL-1β, IL-18) regulate PCSK9 secretion from macrophages and multiple tissues; IL-1β is identified as more important than IL-18 in inducing PCSK9 secretion; MAPKs are involved. High-fat diet-induced PCSK9 secretion is attenuated in IL-1β-deficient mice.\",\n      \"method\": \"Gene deletion mice (NLRP3 KO, IL-1β KO, IL-18 KO, caspase-1 KO), mouse peritoneal macrophages in vitro, high-fat diet in vivo model, PCSK9 secretion measurement\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic knockouts with pathway dissection; single lab\",\n      \"pmids\": [\"32641981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LRP5 forms a physical complex with PCSK9 in lipid-loaded macrophages, and both contribute to macrophage lipid uptake. In the absence of both LRP5 and PCSK9, cholesterol ester accumulation is strongly reduced. LRP5 silencing also reduces soluble PCSK9 release, indicating LRP5 participates in PCSK9 secretion. PCSK9 upregulates TLR4/NF-κB signaling in macrophages after lipid loading.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown of LRP5 and PCSK9 in primary human macrophages, cholesterol ester accumulation assay, NF-κB nuclear translocation assay\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP plus siRNA functional assay; single lab, moderate mechanistic depth\",\n      \"pmids\": [\"32991689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Adenylyl cyclase-associated protein 1 (CAP1) is identified as the main cell-surface binding partner of PCSK9 in macrophages, mediating LDLR-independent pro-inflammatory signaling. PCSK9-CAP1 binding activates spleen tyrosine kinase (Syk) and PKCδ, leading to NF-κB activation and upregulation of TLR4, scavenger receptors, and pro-inflammatory cytokines. In LDLR-knockout mice, AAV-mediated PCSK9 overexpression promotes vein graft lesion development without altering cholesterol levels.\",\n      \"method\": \"Systems biology/transcriptomics, in vitro stimulation of LDLR−/− macrophages with recombinant PCSK9, AAV gain-of-function in Ldlr−/− mice, in vivo molecular imaging, unbiased network analysis identifying CAP1, functional validation with CAP1-Fc fragment\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — LDLR-independent in vivo model combined with unbiased transcriptomics, binding partner identification, and kinase pathway validation with functional antagonism; multiple orthogonal methods\",\n      \"pmids\": [\"38555386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The C-terminal Cys/His-rich domain (CHRD) of PCSK9 is required (in addition to catalytic domain binding to EGF-A of LDLR) for PCSK9 function; CHRD binds the secreted cytosolic cyclase associated protein 1 (CAP1), and this interaction is necessary for PCSK9-mediated LDLR degradation.\",\n      \"method\": \"Structural and biochemical analyses, domain-deletion studies, binding assays cited in review with primary data\",\n      \"journal\": \"Endocrine reviews\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multi-domain functional dissection cited across multiple studies; review paper summarizing primary data\",\n      \"pmids\": [\"35552680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PCSK9 prevents the acidic pH-induced conformational change in the LDLR extracellular domain that is required for LDLR interaction with SNX17 (sorting nexin 17) via the LDLR intracellular domain. SNX17 is required for LDLR recycling; knocking down SNX17 abolishes LDLR recycling and causes lysosomal degradation. PCSK9 blocks SNX17 binding to LDLR, thereby diverting LDLR to lysosomal degradation. FH-associated sequence variations that disrupt LDLR recycling are unresponsive to PCSK9 or PCSK9 inhibitors.\",\n      \"method\": \"SNX17 knockdown in cells and in vivo, LDLR knockout HuH7 cells and mice reconstituted with FH variants, conformational assays, co-immunoprecipitation of LDLR-SNX17 interaction at neutral vs. acidic pH, PCSK9 binding assays\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mechanistic reconstitution in vitro and in vivo with SNX17 knockdown epistasis, pH-dependent conformational assays, and FH variant functional testing; multiple orthogonal approaches in one study\",\n      \"pmids\": [\"40071387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PCSK9 inhibition in hepatocytes enhances the nuclear expression of PPARα by diminishing its lysosomal degradation, which subsequently activates CYP7A1 transcription and increases conversion of cholesterol to bile acids, preventing cholesterol gallstone formation in mice.\",\n      \"method\": \"In vitro PCSK9 inhibition in hepatocytes, nuclear/cytosolic fractionation for PPARα, PPARα lysosomal degradation assay, CYP7A1 promoter-reporter assay, CGS mouse model with alirocumab treatment\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic cell-based pathway dissection plus in vivo mouse model; single lab\",\n      \"pmids\": [\"38191052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PCSK9 expression level in pancreatic ductal adenocarcinoma cells determines metastatic organ preference: PCSK9-low cells preferentially colonize the LDL-rich liver (importing LDL-cholesterol to activate mTORC1 and generate signaling oxysterol 24(S)-hydroxycholesterol), whereas PCSK9-high cells colonize the lung by upregulating distal cholesterol synthesis intermediates (7-dehydrocholesterol, 7-dehydrodesmosterol) that protect against ferroptosis. Increasing PCSK9 redirects liver-avid cells to the lung; ablating PCSK9 drives lung-avid cells to the liver.\",\n      \"method\": \"In vivo mouse metastasis modeling, gene expression correlation analysis, PCSK9 overexpression and genetic ablation in PDAC cell lines, mTORC1 activity assays, oxysterol quantification, ferroptosis assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — gain- and loss-of-function in vivo with mechanistic metabolic pathway dissection; multiple orthogonal methods, single study\",\n      \"pmids\": [\"40399683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Annexin A2 specifically binds the C-terminal Cys/His-rich domain (CHRD) of PCSK9 and inhibits its function on LDLR degradation, identifying CHRD as a functional domain and Annexin A2 as an endogenous inhibitor.\",\n      \"method\": \"Binding assays, PCSK9 domain mapping, LDLR degradation assay with Annexin A2\",\n      \"journal\": \"Expert opinion on therapeutic targets\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — binding domain identification with functional inhibition assay; cited as established finding across multiple reviews\",\n      \"pmids\": [\"19063703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Circulating PCSK9 binds to apolipoprotein B100 on LDL particles, which inhibits PCSK9's ability to bind to cell surface LDLRs, providing a negative feedback mechanism on PCSK9 activity.\",\n      \"method\": \"Biochemical binding assays (PCSK9-LDL interaction), LDLR binding competition assays\",\n      \"journal\": \"Current opinion in lipidology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — binding assay data summarized in review; single experimental approach\",\n      \"pmids\": [\"25110901\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PCSK9 is a secreted serine protease that undergoes autocatalytic ER processing of its prosegment; once secreted, it binds via its catalytic domain to the EGF-A domain of LDLR at the hepatocyte surface, is co-internalized by clathrin-mediated endocytosis, and at acidic endosomal pH exploits an additional electrostatic interaction between its C-terminal CHRD and the LDLR ligand-binding domain to prevent LDLR from adopting the closed conformation needed for recycling and from interacting with the recycling adaptor SNX17, thereby diverting LDLR to lysosomal degradation in a non-enzymatic (chaperone) fashion; beyond LDLR, PCSK9 also promotes lysosomal degradation of MHC-I and other receptors, activates LDLR-independent inflammatory signaling through a CAP1–Syk–PKCδ–NF-κB axis, and its expression level in cancer cells governs cholesterol metabolic reprogramming that dictates metastatic organ tropism.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PCSK9 is a secreted proteinase K-like subtilase that governs LDL cholesterol metabolism by controlling the surface abundance of the LDL receptor (LDLR), and human gain-of-function mutations (S127R, D374Y) in PCSK9 cause autosomal dominant hypercholesterolemia [#1]. The protein matures by Ca2+-independent autocatalytic intramolecular cleavage of its prosegment at an (Y,I)VV(V,L)(L,M) motif in the ER, with hydrophobic residues at P1/P3/P5 critical for recognition, after which the mature convertase is secreted [#0, #2, #6]. Its proteolytic activity is dispensable for LDLR regulation: instead PCSK9 acts as a chaperone, binding LDLR and routing it to lysosomal degradation rather than recycling [#3, #9]. Mechanistically, the PCSK9 catalytic domain engages the EGF-A domain of LDLR at the cell surface; after clathrin-mediated co-internalization, an acidic-pH electrostatic interaction with the LDLR ligand-binding domain holds the complex together and blocks the conformational change LDLR needs to recycle [#10], specifically preventing LDLR from binding the recycling adaptor SNX17 and thereby diverting it to lysosomal destruction [#17]. The C-terminal Cys/His-rich domain (CHRD) is a second functional module required for full activity; it is bound and inhibited by Annexin A2 and engages CAP1 in support of LDLR degradation [#16, #20]. Beyond LDLR, PCSK9 drives lysosomal degradation of MHC class I on tumor cells, dampening cytotoxic T-cell infiltration so that its blockade potentiates anti-PD1 therapy [#12], and it activates LDLR-independent pro-inflammatory signaling through cell-surface CAP1, triggering a Syk\\u2013PKC\\u03b4\\u2013NF-\\u03baB axis that upregulates TLR4, scavenger receptors, and cytokines [#15]. PCSK9 secretion is itself induced by NLRP3 inflammasome/IL-1\\u03b2 signaling [#13], and its expression level in pancreatic cancer cells reprograms cholesterol metabolism to dictate metastatic organ tropism between liver and lung [#19].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established the enzymatic identity of PCSK9, answering how the newly identified protein matures and what cleavage specificity governs its zymogen processing.\",\n      \"evidence\": \"Biosynthetic analysis, microsequencing, in vitro peptide processing, and Ala-scanning across P1-P5 of recombinant enzyme\",\n      \"pmids\": [\"12552133\", \"14622975\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify physiological substrates beyond the prosegment\", \"Did not connect the protease activity to a cellular function\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Connected PCSK9 to human disease, answering whether the protein has a physiological role in lipid homeostasis by linking specific mutations to hypercholesterolemia.\",\n      \"evidence\": \"Linkage mapping and mutation identification in autosomal dominant hypercholesterolemia kindreds\",\n      \"pmids\": [\"12730697\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the molecular mechanism by which mutations raise LDL\", \"Did not distinguish gain- versus loss-of-function consequences mechanistically\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed PCSK9 acts on the LDLR and operates in vivo, answering whether PCSK9 controls LDL by degrading the receptor and whether the effect is LDLR-dependent.\",\n      \"evidence\": \"Stable HepG2 overexpression with ammonium chloride inhibition, adenoviral hepatic overexpression in WT and LDLR-/- mice, and characterization of mutant zymogen processing\",\n      \"pmids\": [\"15358785\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve whether catalytic activity was required for LDLR loss\", \"The LDLR-independent ~2-fold effect in LDLR-/- mice was unexplained\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Localized the maturation and trafficking of PCSK9, addressing where processing occurs and how the secreted protein intersects the LDLR endocytic route.\",\n      \"evidence\": \"Subcellular fractionation and confocal double-immunofluorescence with LDLR and clathrin antibodies\",\n      \"pmids\": [\"16462892\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Colocalization was partial and correlative\", \"Did not demonstrate direct co-trafficking of a PCSK9-LDLR complex\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Probed non-hepatic roles, testing whether PCSK9 has functions outside cholesterol metabolism in the nervous system.\",\n      \"evidence\": \"Morpholino knockdown in zebrafish with neuroanatomical phenotyping, and overexpression with active-site/deletion mutants in primary cerebellar granule neurons\",\n      \"pmids\": [\"16893422\", \"17051583\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Morpholino specificity and off-target effects not fully excluded\", \"Mechanistic link between protease activity and neuronal apoptosis not defined\", \"Relevance to mammalian CNS unestablished\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Resolved the central mechanistic question of whether PCSK9 needs its protease activity, establishing that it acts as a non-enzymatic chaperone for LDLR degradation.\",\n      \"evidence\": \"Catalytic-site mutagenesis combined with crystal structure determination and LDLR degradation assays\",\n      \"pmids\": [\"18649882\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the endosomal trafficking step that commits LDLR to lysosomes\", \"Did not explain how the complex evades recycling\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified the CHRD as a functional domain and an endogenous regulator, addressing how PCSK9 activity can be modulated post-secretion.\",\n      \"evidence\": \"Domain mapping and binding assays with Annexin A2, plus LDLR degradation assays\",\n      \"pmids\": [\"19063703\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of Annexin A2-CHRD binding not resolved\", \"Physiological extent of Annexin A2 regulation in vivo unquantified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Assembled the molecular model of how PCSK9 traps LDLR, answering how a surface-binding event is converted into lysosomal diversion and how circulating PCSK9 is buffered.\",\n      \"evidence\": \"Mechanistic synthesis of structural/biochemical data on EGF-A binding and acidic-pH C-terminal interaction; biochemical apoB100-PCSK9 binding and LDLR competition assays\",\n      \"pmids\": [\"25222343\", \"25110901\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the recycling-blocking adaptor not yet defined\", \"In vivo relevance of the apoB100 feedback not quantified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extended PCSK9 into vascular inflammation, addressing whether PCSK9 participates in atherogenic signaling independent of hepatic lipid handling.\",\n      \"evidence\": \"Reciprocal siRNA/overexpression and LOX-1 and PCSK9 knockout mice with mtROS manipulation; NF-kB/VCAM-1 readouts\",\n      \"pmids\": [\"26092101\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct physical interaction not demonstrated\", \"Causal direction of the LOX-1/PCSK9 loop incompletely resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined an immune function for PCSK9, answering whether it regulates antigen presentation and could be leveraged in cancer immunotherapy.\",\n      \"evidence\": \"Co-immunoprecipitation, PCSK9 deletion and neutralizing antibody in syngeneic tumors, MHC-I flow cytometry, and T-cell depletion epistasis\",\n      \"pmids\": [\"33177715\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Domain of PCSK9 mediating MHC-I binding not mapped\", \"Whether MHC-I degradation uses the same trafficking machinery as LDLR unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified an upstream regulator of PCSK9 release, addressing how inflammation controls PCSK9 levels.\",\n      \"evidence\": \"NLRP3, IL-1b, IL-18 and caspase-1 knockout mice, macrophages, and high-fat diet model measuring PCSK9 secretion\",\n      \"pmids\": [\"32641981\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which IL-1b drives secretion not defined\", \"Tissue source contributions not fully separated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linked PCSK9 to macrophage lipid uptake and secretion, addressing partners that act with PCSK9 in foam-cell formation.\",\n      \"evidence\": \"Co-IP and siRNA of LRP5 and PCSK9 in primary human macrophages with cholesterol ester and NF-kB assays\",\n      \"pmids\": [\"32991689\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab Co-IP without structural mapping\", \"Whether LRP5 is a PCSK9 degradation substrate or a secretion cofactor unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified the receptor for LDLR-independent inflammatory signaling, answering how secreted PCSK9 transmits a pro-inflammatory signal at the cell surface.\",\n      \"evidence\": \"Unbiased transcriptomics, recombinant PCSK9 stimulation of LDLR-/- macrophages, CAP1 identification with CAP1-Fc antagonism, and AAV PCSK9 in Ldlr-/- mice with molecular imaging\",\n      \"pmids\": [\"38555386\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of PCSK9-CAP1 engagement not solved\", \"How CAP1 couples to Syk activation mechanistically unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Connected the CHRD to CAP1 in LDLR degradation, addressing the role of the second PCSK9 domain in receptor turnover.\",\n      \"evidence\": \"Domain-deletion and binding studies summarized with primary data\",\n      \"pmids\": [\"35552680\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review-level synthesis rather than single primary dataset\", \"Quantitative contribution of CHRD-CAP1 versus catalytic-EGF-A binding not separated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Revealed a hepatic bile-acid axis controlled by PCSK9, addressing downstream metabolic consequences of PCSK9 inhibition.\",\n      \"evidence\": \"Hepatocyte PCSK9 inhibition, PPARa nuclear/lysosomal fractionation, CYP7A1 promoter-reporter, and gallstone mouse model with alirocumab\",\n      \"pmids\": [\"38191052\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PCSK9 directly degrades PPARa or acts indirectly unresolved\", \"Single-lab in vivo model\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Pinpointed the recycling step PCSK9 blocks, answering precisely how PCSK9 converts endosomal LDLR from recycling to degradation.\",\n      \"evidence\": \"SNX17 knockdown in cells and in vivo, LDLR-/- HuH7 cells and mice reconstituted with FH variants, pH-dependent conformational and co-IP assays\",\n      \"pmids\": [\"40071387\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the LDLR-SNX17 interface not solved\", \"Why some FH variants are intrinsically PCSK9-unresponsive at atomic detail unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Established PCSK9 as a determinant of cancer metastatic tropism, addressing how PCSK9 expression reprograms cholesterol metabolism to dictate organ colonization.\",\n      \"evidence\": \"In vivo PDAC metastasis modeling with PCSK9 overexpression/ablation, mTORC1 assays, oxysterol quantification, and ferroptosis assays\",\n      \"pmids\": [\"40399683\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether tropism control depends on secreted versus intracellular PCSK9 unresolved\", \"Generalizability beyond pancreatic cancer untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How PCSK9 selects and traffics its non-LDLR targets (MHC-I and other receptors) and whether a single structural mechanism unifies its chaperone, inflammatory, and metabolic-reprogramming functions remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No shared structural model linking LDLR, MHC-I, and CAP1 engagement\", \"Domain requirements for non-LDLR cargo degradation unmapped\", \"Relative in vivo contribution of intracellular versus secreted PCSK9 to each function unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 6]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [9, 10, 17]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [10, 17]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [3, 10, 12]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [10, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 4, 19]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [10, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [12, 13, 15]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [15]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 9]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"LDLR\", \"CAP1\", \"MHC class I\", \"ANXA2\", \"LRP5\", \"SNX17\", \"APOB\", \"LOX-1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}